Heart failure (HF) affects 5.7 million men and women in the United States, with 915,000 new cases occurring annually and a resultant 1,000,000 hospitalizations, which translates into an annual estimated cost of over $30 billion dollars. Mortality with this condition is high, approximately 50% at five years. Implementation of the advances in management of heart failure have the potential to improve patients' quality of life, reduce the need for hospitalizations, reduce total medical costs, and prolong survival. This lecture will review the current evidence-based, guideline recommended diagnosis and management of heart failure. The essential roles of evidence-based heart failure medications, device therapy, patient education, and disease management will be discussed.
This session will review a number of clinically relevant trials/topics recently presented at the American College of Cardiology Scientific Sessions in March 2017, including updates in the management of patients with hypercholesterolemia, heart failure, valvular heart disease, arrhythmias, and more.